Q8R5F7
PR
Gene name |
Ifih1 |
Protein name |
Interferon-induced helicase C domain-containing protein 1 |
Names |
Helicase with 2 CARD domains, Helicard, Interferon induced with helicase C domain protein 1, Melanoma differentiation-associated protein 5, MDA-5, RIG-I-like receptor 2, RLR-2 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:71586 |
EC number |
3.6.4.13: Acting on ATP; involved in cellular and subcellular movement |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
15 structures for Q8R5F7
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 3TS9 | X-ray | 200 A | A | 545-697 | PDB |
| 6G19 | EM | 368 A | A | 307-1020 | PDB |
| 6G1S | EM | 393 A | A | 310-1020 | PDB |
| 6G1X | EM | 393 A | A | 307-1020 | PDB |
| 6GJZ | EM | 406 A | A | 1-1025 | PDB |
| 6GKH | EM | 406 A | A | 1-1025 | PDB |
| 6GKM | EM | 387 A | A | 1-1025 | PDB |
| 6H61 | EM | 402 A | A | 1-1025 | PDB |
| 6H66 | EM | 416 A | A | 1-1025 | PDB |
| 7BKP | EM | 280 A | A | 1-1025 | PDB |
| 7BKQ | EM | 340 A | A | 307-1020 | PDB |
| 7NGA | EM | 390 A | A | 1-1025 | PDB |
| 7NIC | EM | 430 A | A | 1-1025 | PDB |
| 7NIQ | EM | 430 A | B | 1-1025 | PDB |
| AF-Q8R5F7-F1 | Predicted | AlphaFoldDB |
51 variants for Q8R5F7
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs262269105 | 48 | K>R | No | EVA | |
| rs3388555534 | 74 | G>* | No | EVA | |
| rs52041883 | 100 | T>I | No | EVA | |
| rs217525769 | 105 | P>T | No | EVA | |
| rs213982006 | 201 | G>D | No | EVA | |
| rs48373454 | 216 | D>E | No | EVA | |
| rs28039410 | 235 | T>A | No | EVA | |
| rs241441954 | 240 | V>A | No | EVA | |
| rs28039411 | 250 | T>I | No | EVA | |
| rs3388556460 | 269 | C>W | No | EVA | |
| rs28039507 | 297 | Q>R | No | EVA | |
| rs3388557531 | 330 | L>I | No | EVA | |
| rs3388557557 | 331 | P>L | No | EVA | |
| rs3388554082 | 336 | K>E | No | EVA | |
| rs3388554120 | 338 | R>* | No | EVA | |
| rs3388554046 | 356 | E>K | No | EVA | |
| rs3413084151 | 365 | N>K | No | EVA | |
| rs3388546736 | 380 | P>S | No | EVA | |
| rs3388551929 | 426 | E>V | No | EVA | |
| rs3388550102 | 428 | G>D | No | EVA | |
| rs3388551940 | 475 | Q>L | No | EVA | |
| rs3388556632 | 513 | N>S | No | EVA | |
| rs3388546701 | 517 | F>Y | No | EVA | |
| rs3388550151 | 518 | T>A | No | EVA | |
| rs3388552010 | 537 | C>F | No | EVA | |
| rs220180724 | 560 | A>G | No | EVA | |
| rs3388555511 | 569 | S>G | No | EVA | |
| rs3391616432 | 644 | D>* | No | EVA | |
| rs3391589181 | 645 | S>C | No | EVA | |
| rs28039556 | 647 | K>E | No | EVA | |
| rs3391648445 | 647 | K>S | No | EVA | |
| rs3391722407 | 780 | T>S | No | EVA | |
| rs3388556439 | 827 | E>V | No | EVA | |
| rs3388546763 | 837 | G>D | No | EVA | |
| rs3388555581 | 853 | M>I | No | EVA | |
| rs3388553193 | 857 | A>T | No | EVA | |
| rs3388546713 | 860 | R>H | No | EVA | |
| rs3388557562 | 871 | H>Y | No | EVA | |
| rs3391589225 | 890 | R>S | No | EVA | |
| rs3391694018 | 891 | S>C | No | EVA | |
| rs3391694064 | 894 | K>* | No | EVA | |
| rs265918988 | 898 | D>N | No | EVA | |
| rs3388558882 | 949 | K>M | No | EVA | |
| rs1133012289 | 967 | A>S | No | EVA | |
| rs1132208039 | 968 | W>C | No | EVA | |
| rs1133619128 | 969 | G>R | No | EVA | |
| rs1133279170 | 970 | T>R | No | EVA | |
| rs1134800134 | 971 | M>R | No | EVA | |
| rs28039597 | 996 | P>L | No | EVA | |
| rs3412537013 | 1001 | K>N | No | EVA | |
| rs3388551934 | 1021 | Y>C | No | EVA |
No associated diseases with Q8R5F7
7 regional properties for Q8R5F7
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Helicase, C-terminal | 700 - 872 | IPR001650 |
| domain | Helicase/UvrB, N-terminal | 307 - 492 | IPR006935 |
| domain | Helicase superfamily 1/2, ATP-binding domain | 305 - 520 | IPR014001 |
| domain | RIG-I-like receptor, C-terminal regulatory domain | 893 - 1020 | IPR021673 |
| domain | Caspase recruitment domain | 9 - 97 | IPR031964-1 |
| domain | Caspase recruitment domain | 111 - 199 | IPR031964-2 |
| domain | RIG-I-like receptor, C-terminal | 538 - 692 | IPR041204 |
Functions
| Description | ||
|---|---|---|
| EC Number | 3.6.4.13 | Acting on ATP; involved in cellular and subcellular movement |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| mitochondrion | A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
10 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| ATP hydrolysis activity | Catalysis of the reaction: ATP + H2O = ADP + H+ phosphate. ATP hydrolysis is used in some reactions as an energy source, for example to catalyze a reaction or drive transport against a concentration gradient. |
| DNA binding | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
| double-stranded RNA binding | Binding to double-stranded RNA. |
| identical protein binding | Binding to an identical protein or proteins. |
| ribonucleoprotein complex binding | Binding to a complex of RNA and protein. |
| RNA binding | Binding to an RNA molecule or a portion thereof. |
| RNA helicase activity | Unwinding of an RNA helix, driven by ATP hydrolysis. |
| single-stranded RNA binding | Binding to single-stranded RNA. |
| zinc ion binding | Binding to a zinc ion (Zn). |
12 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to exogenous dsRNA | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an exogenous double-stranded RNA stimulus. |
| defense response to virus | Reactions triggered in response to the presence of a virus that act to protect the cell or organism. |
| innate immune response | Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. |
| MDA-5 signaling pathway | The series of molecular signals initiated by viral RNA binding of a cytoplasmic pattern recognition receptor (PRR) MDA-5 (also known as IFIH1). MDA-5 is a cytoplasmic receptor that detects RNA synthesized during viral replication and triggers a signaling pathway to protect the host against viral infection, for example by inducing the expression of antiviral cytokines. |
| negative regulation of viral genome replication | Any process that stops, prevents, or reduces the frequency, rate or extent of viral genome replication. |
| positive regulation of interferon-alpha production | Any process that activates or increases the frequency, rate, or extent of interferon-alpha production. |
| positive regulation of interferon-beta production | Any process that activates or increases the frequency, rate, or extent of interferon-beta production. |
| positive regulation of interleukin-6 production | Any process that activates or increases the frequency, rate, or extent of interleukin-6 production. |
| positive regulation of response to cytokine stimulus | Any process that increases the rate, frequency, or extent of a response to cytokine stimulus. |
| positive regulation of tumor necrosis factor production | Any process that activates or increases the frequency, rate or extent of tumor necrosis factor production. |
| protein sumoylation | The process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxy-terminus of SUMO with an epsilon-amino group of a lysine residue of the target protein. |
| response to virus | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. |
8 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| O95786 | RIGI | Antiviral innate immune response receptor RIG-I | Homo sapiens (Human) | EV |
| Q96C10 | DHX58 | ATP-dependent RNA helicase DHX58 | Homo sapiens (Human) | PR |
| Q9BYX4 | IFIH1 | Interferon-induced helicase C domain-containing protein 1 | Homo sapiens (Human) | PR |
| Q9UPY3 | DICER1 | Endoribonuclease Dicer | Homo sapiens (Human) | EV |
| Q6Q899 | Ddx58 | Antiviral innate immune response receptor RIG-I | Mus musculus (Mouse) | SS |
| Q9GLV6 | DDX58 | Antiviral innate immune response receptor RIG-I | Sus scrofa (Pig) | SS |
| P34529 | dcr-1 | Endoribonuclease dcr-1 | Caenorhabditis elegans | PR |
| Q6TV19 | dicer1 | Endoribonuclease Dicer | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSIVCSAEDS | FRNLILFFRP | RLKMYIQVEP | VLDHLIFLSA | ETKEQILKKI | NTCGNTSAAE |
| 70 | 80 | 90 | 100 | 110 | 120 |
| LLLSTLEQGQ | WPLGWTQMFV | EALEHSGNPL | AARYVKPTLT | DLPSPSSETA | HDECLHLLTL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LQPTLVDKLL | INDVLDTCFE | KGLLTVEDRN | RISAAGNSGN | ESGVRELLRR | IVQKENWFST |
| 190 | 200 | 210 | 220 | 230 | 240 |
| FLDVLRQTGN | DALFQELTGG | GCPEDNTDLA | NSSHRDGPAA | NECLLPAVDE | SSLETEAWNV |
| 250 | 260 | 270 | 280 | 290 | 300 |
| DDILPEASCT | DSSVTTESDT | SLAEGSVSCF | DESLGHNSNM | GRDSGTMGSD | SDESVIQTKR |
| 310 | 320 | 330 | 340 | 350 | 360 |
| VSPEPELQLR | PYQMEVAQPA | LDGKNIIICL | PTGSGKTRVA | VYITKDHLDK | KKQASESGKV |
| 370 | 380 | 390 | 400 | 410 | 420 |
| IVLVNKVMLA | EQLFRKEFNP | YLKKWYRIIG | LSGDTQLKIS | FPEVVKSYDV | IISTAQILEN |
| 430 | 440 | 450 | 460 | 470 | 480 |
| SLLNLESGDD | DGVQLSDFSL | IIIDECHHTN | KEAVYNNIMR | RYLKQKLRNN | DLKKQNKPAI |
| 490 | 500 | 510 | 520 | 530 | 540 |
| PLPQILGLTA | SPGVGAAKKQ | SEAEKHILNI | CANLDAFTIK | TVKENLGQLK | HQIKEPCKKF |
| 550 | 560 | 570 | 580 | 590 | 600 |
| VIADDTRENP | FKEKLLEIMA | SIQTYCQKSP | MSDFGTQHYE | QWAIQMEKKA | AKDGNRKDRV |
| 610 | 620 | 630 | 640 | 650 | 660 |
| CAEHLRKYNE | ALQINDTIRM | IDAYSHLETF | YTDEKEKKFA | VLNDSDKSDD | EASSCNDQLK |
| 670 | 680 | 690 | 700 | 710 | 720 |
| GDVKKSLKLD | ETDEFLMNLF | FDNKKMLKKL | AENPKYENEK | LIKLRNTILE | QFTRSEESSR |
| 730 | 740 | 750 | 760 | 770 | 780 |
| GIIFTKTRQS | TYALSQWIME | NAKFAEVGVK | AHHLIGAGHS | SEVKPMTQTE | QKEVISKFRT |
| 790 | 800 | 810 | 820 | 830 | 840 |
| GEINLLIATT | VAEEGLDIKE | CNIVIRYGLV | TNEIAMVQAR | GRARADESTY | VLVTSSGSGV |
| 850 | 860 | 870 | 880 | 890 | 900 |
| TEREIVNDFR | EKMMYKAINR | VQNMKPEEYA | HKILELQVQS | ILEKKMKVKR | SIAKQYNDNP |
| 910 | 920 | 930 | 940 | 950 | 960 |
| SLITLLCKNC | SMLVCSGENI | HVIEKMHHVN | MTPEFKGLYI | VRENKALQKK | FADYQTNGEI |
| 970 | 980 | 990 | 1000 | 1010 | 1020 |
| ICKCGQAWGT | MMVHKGLDLP | CLKIRNFVVN | FKNNSPKKQY | KKWVELPIRF | PDLDYSEYCL |
| YSDED |